Literature DB >> 15081793

Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors.

Leyre Urigüen1, Sandra Pérez-Rial, Catherine Ledent, Tomás Palomo, Jorge Manzanares.   

Abstract

The role of cannabinoid CB(1) receptors in the action of anxiolytics was examined. Deletion of CB(1) receptors resulted in increased anxiety-like behaviours in light/dark box, elevated plus maze and social interaction tests. Mutant mice presented basal low corticosterone concentrations and low proopiomelanocortin gene expression in the anterior lobe of the pituitary gland compared to wild-type mice. Ten minutes of restraint stress resulted in a twofold increase in corticosterone concentrations in the plasma of mutant mice, compared to wild-type mice. Bromazepam (50 or 100 microg/kg) markedly increased the time spent in light area in wild-type animals, though both doses were without effect in mutant mice. Administration of buspirone (1 or 2 mg/kg) produced anxiolytic effects in wild-type mice. In contrast, only the highest dose of buspirone had anxiolytic results in mutant mice. Our findings reveal that CB(1) receptors are involved in the regulation of emotional responses, and play a pivotal role in the action mechanism of anxiolytics. They suggest that alterations in the functional activity of the CB(1) receptor may be related to the emergence of anxiety disorders, and may affect treatment with anxiolytics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15081793     DOI: 10.1016/j.neuropharm.2004.01.003

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  55 in total

1.  Cannabinoid receptor type 1 antagonism significantly modulates basal and loud noise induced neural and hypothalamic-pituitary-adrenal axis responses in male Sprague-Dawley rats.

Authors:  R J Newsom; C Osterlund; C V Masini; H E Day; R L Spencer; S Campeau
Journal:  Neuroscience       Date:  2011-11-28       Impact factor: 3.590

Review 2.  Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.

Authors:  Celina S Liu; Sarah A Chau; Myuri Ruthirakuhan; Krista L Lanctôt; Nathan Herrmann
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

Review 3.  Enhancement of endocannabinoid signaling and the pharmacotherapy of depression.

Authors:  Regina A Mangieri; Daniele Piomelli
Journal:  Pharmacol Res       Date:  2007-09-11       Impact factor: 7.658

4.  Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.

Authors:  Matthew N Hill; Erica J Carrier; Ryan J McLaughlin; Anna C Morrish; Sarah E Meier; Cecilia J Hillard; Boris B Gorzalka
Journal:  J Neurochem       Date:  2008-07-15       Impact factor: 5.372

Review 5.  The endocannabinoid system as a target for the treatment of cannabis dependence.

Authors:  Jason R Clapper; Regina A Mangieri; Daniele Piomelli
Journal:  Neuropharmacology       Date:  2008-07-19       Impact factor: 5.250

Review 6.  Endocannabinoid-mediated synaptic plasticity and addiction-related behavior.

Authors:  Nimish Sidhpura; Loren H Parsons
Journal:  Neuropharmacology       Date:  2011-06-12       Impact factor: 5.250

7.  Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions.

Authors:  Mathieu Lafourcade; Thomas Larrieu; Susana Mato; Anais Duffaud; Marja Sepers; Isabelle Matias; Veronique De Smedt-Peyrusse; Virginie F Labrousse; Lionel Bretillon; Carlos Matute; Rafael Rodríguez-Puertas; Sophie Layé; Olivier J Manzoni
Journal:  Nat Neurosci       Date:  2011-01-30       Impact factor: 24.884

Review 8.  Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.

Authors:  Ryan Wyrofsky; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Expert Opin Drug Discov       Date:  2014-12-09       Impact factor: 6.098

Review 9.  Involvement of the endocannabinoid system in the neurobehavioural effects of stress and glucocorticoids.

Authors:  Matthew N Hill; Bruce S McEwen
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-11-10       Impact factor: 5.067

Review 10.  Role of endocannabinoid system in mental diseases.

Authors:  Jorge Manzanares; Leyre Urigüen; Gabriel Rubio; Tomás Palomo
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.